Solicitation - BARDA Accelerator Network 2.0 - Supplemental Announcement to Fill Diagnostics and Medical Devices Hub Vacancy

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

26-BARDA-SOL-BAN_2_1

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Washington, District of Columbia, UNITED STATES

SourceSAM
Documents3
The Office of Biomedical Advanced Research and Development Authority (BARDA), operating within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), has released a solicitation seeking to establish a partnership for the development and operation of the Diagnostics/Medical Devices Hub under the BARDA Accelerator Network 2.0 (BAN 2.0) initiative. This supplemental announcement is specifically intended to fill a vacancy within the Diagnostics and Medical Devices Hub, leveraging BARDA’s Other Transaction Authority (OTA) to foster innovation and commercialization in health security. The primary purpose of this procurement is to build and manage the next iteration of the Diagnostics/Medical Devices Hub, which will serve as a critical component of the broader BAN 2.0 network. The envisioned Accelerator Hub will play a pivotal role in enhancing the global health security innovation ecosystem by providing comprehensive acceleration services to innovators and companies focused on diagnostics and medical devices. The scope of work includes supporting product development, evaluation, and validation of medical countermeasures (MCMs), both during routine operations and in rapid response to public health emergencies. Key objectives and deliverables for the selected partner include: - Delivering wraparound acceleration services such as entrepreneurship education, business and commercialization support, and access to technical expertise and resources tailored to BARDA-aligned innovators in the diagnostics and medical devices sector. - Providing BARDA with robust capabilities to source, review, fund, and accelerate the development of innovative solutions, with a focus on product development, evaluation, and validation aligned with BARDA’s strategic priorities. - Establishing a rapid emergency response infrastructure capable of expediting the funding and acceleration of MCMs for swift deployment during public health crises. The Diagnostics/Medical Devices Hub will emphasize solutions that enable pathogen-agnostic surveillance, detection, and diagnosis—particularly at point-of-care and at-home settings—as well as innovative medical devices that enhance casualty care, facilitate early detection of adverse health conditions, streamline sample collection or processing, and protect respiratory health. BARDA is open to proposals from individual organizations or consortia, provided that a single legal entity is designated as the prime awardee responsible for entering into the agreement. The Accelerator Hub is expected to provide funding and services to relevant innovators nationwide, irrespective of the physical location of the Hub itself. This solicitation supersedes all previous announcements related to the BAN 2.0 program; all prior terms and conditions are replaced by those outlined in this notice and any subsequent amendments. Interested parties are advised to rely exclusively on this version for submission, evaluation, and award requirements. The procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with no set-aside restrictions, making it open to all qualified entities. The place of performance is Washington, District of Columbia, though the scope of support is national. The contracting entity is BARDA - ASPR / DAAPPO / BARDA DCMA, a federal office within the Department of Health and Human Services, specifically under the Office of the Assistant Secretary for Preparedness and Response. The primary point of contact for this solicitation is Caleb Owen, who can be reached at [email protected]. Key dates for this opportunity include a submission deadline of 12:00 PM ET on April 20, 2026, and a deadline for questions at 12:00 PM ET on April 2, 2026. BARDA reserves the right to amend the closing date as necessary. Additional details and solicitation documents are available via the provided SAM.gov link and at https://drive.hhs.gov/. This opportunity represents a significant initiative for organizations with expertise in biotechnology research and development, particularly those specializing in diagnostics and medical devices, to contribute to national and global health security through innovation and rapid response capabilities.